Curaleaf Launches Free CPD-Accredited Platform to Close Medical Cannabis Training Gap for UK Healthcare Professionals

Curaleaf International, is the important worldwide leader in healthcare cannabis, announced the launch of the Curaleaf Education Platform, offering access to CPD-accredited healthcare cannabis training for medical care professionals in the UK.

A Curaleaf survey of UK GPs found that 4% had received any official education on healthcare cannabis, and 81% described their knowledge of it as limited or non-existent, with 55% proverb they would requires to advance understand medical cannabis before recommending it to a patient.

Though medical cannabis has been permitted in the UK since 2018 and more than 60,000 UK patients have recently accessed it on prescription, formal education on the endocannabinoid technology and cannabis-driven therapeutic remains limited in mainstream healthcare training.

Curaleaf's Education Platform has been industrialized to address this evidence-led education gap, preparing physicians with the governing clarity and practical guidance needed for the safe and compliant incorporation of healthcare cannabis in the medical care practice. It is available online at curaleafeducation.com, the platform brings a structured learning framework in the opening science, core healthcare knowledge, and specialist therapeutic regions. Registration for it is free, and consumers are awarded CPD authorization on completion, continuing from basic to advanced.

The knowledge is structured in the three core regions: Foundations of medical cannabis, core knowledge for clinical practice, and specialist conditions. Understandings are grounded in Curaleaf's investigation, professional expertise, and real-world data from the UK Medical Cannabis Registry - the largest healthcare database of its kind with over 55,000 patients.

Dr Simon Erridge, Research Director at Curaleaf Clinic, said: "I regularly speak with GPs and consultants who want to have informed conversations with their patients about medical cannabis, but simply haven't had the training. What we've built with the Education Platform is what I wish I'd had access to when I started working in this field: clear, evidence-led modules that cut through the noise and give clinicians the confidence to integrate medical cannabis into their practice responsibly."

Juan Martinez, CEO of Curaleaf International, added, "Education is the foundation of responsible access. Every clinician we equip with evidence-based training becomes a more confident, capable prescriber, and that is how we build the trust on which the long-term, sustainable growth of medical cannabis depends."

According to Towards Healthcare, the medical cannabis market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 18.57 billion in 2026 to approximately USD 59.45 billion by 2035, representing a compound annual growth rate (CAGR) of 13.80% from 2026 to 2035, driven by increasing cannabis applications lowering pain and spasticity in patients with MS, reductions tremor, rigidity, and pain in patients with PD, and enhances the quality of life of ALS consumer by increasing appetite, and lessen pain and spasticity. Cannabis is commonly use in the patients with schizophrenia more than healthy controls. Cannabis provides a wide range of medical advantages, such as relief from long-term pain, swelling, neurological conditions, and other health complexities. It is used as a symptom management tool by interacting with the body's endocannabinoid system to manage pain, hunger, and neurological disorders.

About Curaleaf:

Curaleaf International is a subdivision of Curaleaf Holdings Inc., a significant health care and adult patient use cannabis business in the United States, with a wide portfolio of dispensaries, cultivation sites, and produce brands. This company handles cannabis in various ways from plant to patient through a worldwide, integrated supply chain and valued collaboration. From cultivation, producing, extraction, distribution, and prescribing, this industry delivers unequalled quality, consistency, and reliability.

Curaleaf staff provides significant services such as worldwide expertise, integrated with local knowledge, enabling support for diverse patient populations while meeting government obedience. With a full suite of licences and a b sales network, we are building solutions for patients, prescribers, and partners in Europe and the rest of the world. This company works closely with medical care professionals, policymakers, and patient communities to shape a future where evidence-based, cannabis-driven therapies are quickly available to the patients who require them.

A recent report by Towards Healthcare highlights that the medical cannabis market is witnessing growth because doctors and cannabis educators have developed a modified healthcare cannabis treatment plan that is personalized toward reducing patients' symptoms precisely and safely. CBD acts on particular organs in the body, which regulate different functions such as digestion, reproduction, inflammation, perception of pain, wake and sleep cycle, immune system activity, stress and emotional state, heart rate and blood pressure, and thinking and nervous system activity. Medical cannabis is well-developed for its capability to control serious nausea and vomiting induced by chemotherapy. The significant compound THC is also applied to stimulate hunger in patients experiencing life-threatening weight loss.